Kornimate/medical-research-clean huggingface dataset:
survey of lipid goal attainment and mortality in patients with high cardiovascular risk in thailand

Conditions: Dyslipidemia

Summary: the first phase of the study is a hospital-based cross-sectional, epidemiological survey. the required sample size is 1,260 patients from 50 hospitals across thailand. each of the hospital will enroll 10 to 40 consecutive patients, depending on case availability on the date conducting the survey, with dyslipidemia and classified as high risk as defined by the protocol. lipid levels will be based on serological analysis conducted by a local laboratory. for the second phase, each subject will be followed for survival status at 36 months after enrollment. such follow-up will be done by searching the thai national vital event registration database using subjects' population identification number. all activities regarding case selection and data collection will be done by well trained clinical research associates (cras). the cras are from khon kaen university where the statistical coordinating center (scc) for this project is based and are independent of the investigator. random auditing visits will also be performed by auditors independent of the scc. these are to ensure not only high quality data but also protecting right and well being of subjects.


Eligibility criteria:
inclusion criteria: * evidence of high cardiovascular risk * dyslipidemic currently being treated with the same therapy for at least 3 months exclusion criteria: * recent major trauma(within 12 weeks) * recent surgery requiring anesthesia including coronary bypass graft(within 12 weeks) * acute or abrupt change(within 1 month) in usual diet * pregnancy, breast-feeding currently, or postpartum within the last 6 months

Keywords: lipid-lowering
type 1 endoleak : fenestrated custom made endograft (fevar) versus open surgery explantation (osr) : what's the best

Conditions: Aorta Aneurysm

Summary: proximal type 1a endoleak is a worrying complication after endovascular repair of an abdominal aortic aneurysm (evar). the ideal solution is not obvious between relining by fevar and endograft explantation. a retrospective french multicentric study was performed between 2010 and 2023 to compare the outcomes and the efficiency of both technics and propose a decision algorithm for the management of type 1a endoleak after evar.


Eligibility criteria:
inclusion criteria: * type 1a endoleak after evar exclusion criteria: * no
exploring the landscape of injury and repair in the human oesophagus

Conditions: Perforations to the Oesophagus

Summary: the goal of this study limited to working with human tissue samples is to delineate the mechanisms defining appropriate oesophageal injury and repair and to use this information to understand how these rules are dysregulated and result in cancer formation in adult patients undergoing endoluminal vacuum therapy (evt therapy) for the treatment of perforations to the oesophagus. the main question\[s\] it aims to answer are: * to gain a deeper understanding of the processes underlying tissue regeneration and repair in the oesophagus and upper gastro-intestinal tract following physical injury * to identify the similarities in the processes of regeneration and early carcinogenesis participants will take part in the study during their usual evt therapy schedule. tissue brushings and pinch biopsies will also be taken.

tissue injury activates a number of cellular responses to initiate wound healing, resulting in the formation of new tissue within a short span of time and in a controlled fashion. in contrast, cancer results when a tissue mass forms in an unregulated process. understanding the molecular mechanisms behind appropriate wound healing enables us to delineate how this process goes askew in the context of cancer. the goal is to delineate the mechanisms defining appropriate oesophageal injury and repair, and to use this information to understand how these rules are dysregulated and result in cancer formation. in this study, the researchers wish to recruit adult patients undergoing endoluminal vacuum therapy (evt therapy) for the treatment of perforations to the oesophagus in order to collect the discarded evt sponge, biopsies from endoscopies, resected surgical specimens and additional blood samples. the researchers will request consent for access to archived tissue samples from any previous related surgery and some associated clinical metadata. the samples and associated clinical metadata will then be pseudonymised and sent to the wellcome sanger institute. once samples are received at the wellcome sanger institute, they will undergo a number of procedures including but not limited to genome sequencing, this will enable the researchers to gain a better understanding of the wound healing process, specifically how it can sometimes go wrong and lead to the development of cancer.

Eligibility criteria:
inclusion criteria: * male and female patients 18 years old and over who are having elective upper gastro-intestinal surgery where a leak is a recognised complication (but has not occurred) * male and female patients 18 years and over who present acutely with an upper gastro-intestinal leak. exclusion criteria: * patients who do not have a good understanding of the english language
optimal heating temperature in major burns patients

Conditions: Burns; Thermal Injury; Nurse's Role

Summary: pre and post intervention quasi-experimental epidemiological study without a control group will be carried out in large burned patients that will evaluate the influence on metabolic expenditure of the inclusion of active external rewarming in the control of body temperature.

the heavily burned patient requires specific care to prevent hypothermia and maintain body temperature. you are at high risk of developing hypothermia in the acute phase due to heat losses from convection, radiation, evaporation, and conduction. after the acute phase, the patient due to physiological mechanisms and the hypermetabolic response mainly demands a temperature close to 38.5ºc, ruling out the infectious focus. according to the authors, environmental temperatures between 28-33ºc are recommended for the care of these patients to decrease energy expenditure. the research carried out has studied the influence of passive external heating (environmental regulation), without including the influence of active external heating (heat blankets, heating plate ...) or the study of the thermal comfort of large burned patients and of professionals who provide them they attend. a pre and post intervention quasi-experimental epidemiological study without a control group will be carried out in large burned patients that will evaluate the influence on metabolic expenditure of the inclusion of active external rewarming in the control of body temperature. metabolic expenditure will be measured by indirect calorimetry in the usual treatment with passive external rewarming and post-intervention in the combination of passive and active external heating. the combination of passive and active external reheating will previously study the operating temperature in various cases for optimal application, as well as the definition of thermal comfort in the large burn unit. the specific training of the personnel involved in the care of these patients will be required for the application of the evidence-based recommendations and the evaluation of their implementation.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * patients with thermal burns. * patient with high burn criteria according to aba: * 2nd degree burn * patient 18 - 59 years: scq\> 20% * patient\> 60 years or pathology: scq\> 10% * 3rd degree burn * scq\> 10% * patients on mechanical ventilation exclusion criteria: * sepsis criteria according to aba. * enzyme debridement application (data within 24 hours). * 6 hours after a surgical intervention. * after 2 hours after healing burns * patients in hemorrhagic shock

Keywords: nursing energy metabolism hypothermia heating burns thermoregulation
new technologies in the rehabilitation of chronic stroke

Conditions: Stroke; Hemiplegia

Summary: the objective of the current study is to develop and investigate training concepts involving rehabilitation technology, which aim at exploiting the potential for regaining the ability to perform skilled movements by maximizing training intensity and keeping the motivation of patients high. the evaluation focuses on feasibility and cost-benefit analyses

this feasibility project aims to establish an efficient setting for intensive rehabilitation with new technology in four trailblazer clinics. this will enable them to provide intensive therapy to the patients in accordance with the study protocol. if this setting is integrated into the clinical routine, the investigators will be able to collect data to get some first insight into economic and functional data required to calculate changes in socioeconomic costs

Eligibility criteria:
inclusion criteria: * adult patients with residual hemiparesis after cerebrovascular accident * up to 12 months after the event * primary rehabilitation terminated * able to cognitively comprehend the aim of the project with at least 22 points in the montreal cognitive assessment (moca) * general health condition allows for intensive rehabilitative training with limited supervision i.e. clearance and prescription of responsible physician * understand written and spoken german language exclusion criteria: patients with any signs and symptoms showing that the participant is unwilling to participate in the study will result in the patient being excluded from participation any medical condition preventing participation such as severe respiratory disease severe or unstable cardio-circulatory conditions orthopaedic conditions, especially in extremities targeted for rehabilitation such as * fixed joint contractures limiting range of motion * non-consolidated fractures neuro-psychological conditions including cognitive deficits limiting communication or non-cooperation like (self-) aggressive behaviour infections or inflammatory diseases, like osteomyelitis specific absolute contraindication for the training with any of the respective devices: * improper fit of the device, including its harness to relevant extremity(ies) * contraindicated training position (standing, sitting) device specific contraindications will be respected and will lead to the exclusion of the device for that patient.
abscopal effect of radiation in combination with rhgm-csf for metastatic non-small cell lung cancer

Conditions: Lung Cancer Metastatic

Summary: the purpose of this study is to determine whether radiation combined with recombined human granulocyte-macrophage colony stimulating factor(rhgm-csf) is safe and effective for patients with metastatic non-small cell lung cancer.

the prognosis of patients with metastatic non-small cell lung cancer was still poor for those unsuitable for target therapy or immunotherapy. this study is to include patients evaluated as effective or stable disease after first-line chemotherapy or progressed after second-line chemotherapy to evaluate the efficacy and safety of receiving radiotherapy combined with recombined human granulocyte-macrophage colony stimulating factor(rhgm-csf).

Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. histologically proven non-small-cell lung cancer； 3. stage iv according to uicc stage system(version 7,2009), at least with three evaluable abscopal lesions (≥1cm)（excluding intestinal metastasis）; 4. evaluated as effective or stable disease after first-line chemotherapy or progressed after second-line chemotherapy (progression sites were no more than three sites); 5. ecog performance status: 0-1; 6. life expectancy ≥ 3 months. 7. adequate baseline organ and marrow function: absolute neutrophil count greater than 1500 cells per μl, platelet concentration of greater than 50 000 per μl, total bilirubin less than 1•5 times the upper limit of normal (uln), aspartate aminotransferase and alanine aminotransferase less than 2•5 times the uln, and serum creatinine less than 1•5 times the uln; 8. female subjects have a negative urine or serum pregnancy test within 1 week prior to treatment if of childbearing potential; 9. asymptomatic subjects with brain metastasis can be included, but the sites of brain cannot be considered as target sites; 10. asymptomatic subjects with bone metastasis can be included, but the sites of bone cannot be considered as target sites. exclusion criteria: 1. having received immunotherapy within 4 weeks prior to inclusion; 2. allergic to gm-csf, or diagnosed with immune system disease, receiving immunosuppressant, such as prednisone, dexamethasone, methylprednisolone, methotrexate, hydroxychloroquine, cyclophosphamide, azathioprine and so one; 3. receiving treatment of other trials; 4. any unstable systemic disease, including active infection, symptomatic congestive heart failure, myocardial infarction onset six months before included into the group, unstable angina, and severe arrhythmia, uncontrolled chronic lung disease; 5. unwilling to sign consent; 6. women in pregnancy or lactation; 7. other malignancy except for non-melanoma carcinoma of the skin or in situ carcinoma of the cervix.
comparison of 3 rf delivery modes of the qdot catheter for paroxymal atrial fibrillation (af) ablation

Conditions: Atrial Fibrillation

Summary: pulmonary vein isolation is the main treatment of paroxysmal and persistent atrial fibrillation. the aim of our study is to prospectively compare the efficacy and safety of the 3 options of radiofrequency delivery with qdot micro™, with systematic use of catheter stabilization tools and tighter lesions

pulmonary vein isolation (pvi) is the main treatment of paroxysmal and persistant atrial fibrillation. pvi is achieved by point-by-point radiofrequency ablation that creates flexible lesion set within targeted area. pvi using standard ablation catheter with limited power (50w) have been described in case series with favorable efficacy and safety. qdotmicro™ is a radiofrequency ablation catheter that incorporates advanced, high-energy ablation, improved temperature monitoring, optimized irrigation, and higher signal resolution. qdot micro™ provides several options regarding radiofrequency administration : * q-mode : provides high power short duration (hpsd) unitl 50w radiofrequency, * q-mode+ : provides very high power very short duration (vhspd) until 90w radiofrequency, * hybrid q-mode/q-mode+ : is a combination of two methods. in our experience, stability is a prerequisite for pvi with qdot micro™. small series have described encouraging results (85% isolation, unpublished data) with stabilization tools such as low-volume ventilation or apnea, high-rate simualtion, vizigo bi-directional sheath (vizigo™). recently, preliminary animal data argue in favor or reducing the interpoint distance with qdot™. to date, there is no study comparing the 3 options of radiofrequency delivery. the aim of our study is to prospectively compare the efficacity and safety of the 3 options of radiofrequency delivery with qdot micro™, with systematic use of catheter stabilization tools and tighter lesions. the same device is used in all three randomisation groups. the difference between the intervention is the intensity of the radiofrequency applied.

Eligibility criteria:
inclusion criteria: * patient aged 18 or over * first atrial fibrillation ablation * paroxysmal atrial fibillation defined as atrial fibrillation lasting less than 48 hours * early atrial fibrillation defined as atrial fibrillation lastiing between 7 days and 3 months * at least one episode of atrial fibrillation in the year preceding study entry * patient affiliated to a health insurance exclusion criteria: * history of atrial fibrillation ablation (surgery or catheter) * documented left atrial thrombus * left atrial (la) diameter \> 60mm / la area \> 35cm2 / left atrial volulme index (lavi) \> 45ml/m2 * n/stemi replacement or angioplasty or valve within 3 months prior to registration * any contraindication mentioned in the instructions for use of the qdot micro™ bidirectional navigation catheter * patient unable to understand study information * patient deprived of liberty by judicial or administrative decision
evaluation of bay 59-8862 in patients with aggressive, refractory non-hodgkin's lymphoma

Conditions: Lymphoma, Non-Hodgkin

Summary: almost two-thirds of lymphoma cases are non-hodgkin's lymphomas (nhl). nhl is a malignant process that affects lymphoid cells found both in the lymph nodes and extranodally. incidence and mortality rates from nhl are highest in developed countries. while many patients with aggressive nhl are curable with initial anthracycline-containing regimens, the majority of patients will relapse or prove refractory to initial therapy. the prognosis of patients with disease recurrence following a multidrug regimen is also limited. the current protocol is designed to test the safety and efficacy of bay 59-8862 in patients with aggressive refractory non-hodgkin's lymphoma.


Eligibility criteria:
inclusion criteria: - measurable disease as defined by the presence of at least one measurable lesion - failed at least one prior therapy or has achieved remission but has progressed or relapsed within 6 months of therapy - life expectancy of at least 12 weeks - adequate bone marrow, liver and kidney function exclusion criteria: - excluded medical conditions like: pre-existing neuropathy, active heart diseases or ischemia, serious infections, hiv infection, chronic hepatitis b or c, seizures, hypersensitivity to taxanes, organ transplants, some previous cancers - excluded therapies and medications, previous and concomitant such as: anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to study entry; more than two prior anticancer chemotherapy regimens; radiotherapy during study or within 4 weeks prior to study entry; bone marrow transplant - others: pregnant or breast-feeding patients; both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial; substance abuse, medical, psychological or social conditions that may interfere with the patient's participation

Keywords: taxane lymphoma non-hodgkin's lymphoma
clinical cohort study - trust

Conditions: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Ventricular Tachycardia; Atrial Tachycardia; Arrhythmogenic Right Ventricular Dysplasia; Long QT Syndrome; Brugada Syndrome; Supraventricular Tachycardia; Catecholaminergic Polymorphic Ventricular Tachycardia; Torsades De Pointes; Atrial Cardiomyopathy

Summary: the "long-term outcome and predictors for recurrence after medical and interventional treatment of arrhythmias at the university heart center hamburg" (trust) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. the design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the uhz. collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.

arrhythmias such as atrial fibrillation, ventricular tachycardia, and sudden death remain major causes of morbidity and mortality. their prevalence increases in our ageing populations. modern therapy of these conditions, using a combination of drugs, devices, and interventions, can reduce the disease burden associated with cardiac arrhythmias. this prospective cohort study will collect detailed clinical, procedural, and outcome information in a large cohort of patients with arrhythmias seen in a tertiary care center. clinical phenotyping will be enhanced by biosampling and analysis of circulating biomolecules. digital capture of clinical information and of follow-up data is planned.

Eligibility criteria:
inclusion criteria: * cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia * age ≥ 18 years * written informed consent * ability to provide written informed consent in accordance with good clinical practice and local legislation exclusion criteria: * insufficient knowledge of the german language to understand study documents and interview without translation * physical or psychological incapability to cooperate in the investigation

Keywords: catheter ablation biomarkers cardiac arrhythmia ehealth digital cardiology echocardiography atrial cardiomyopathy
systemic treatment options for generalized lichen planus

Conditions: Lichen Planus

Summary: lichen planus is a chronic inflammatory skin condition with unknown etiology. it requires a long term treatment. evaulating the most efficacious, safe and affordable treatment option is the need of the hour. this study is going to compare the efficacy of two familiar drugs (acitretin and methotrexate) in the treatment of generalized lichen planus as to find out the relatively more effective and safer treatment.

lichen planus (lp) is a chronic mucocutaneous condition of an unknown cause. it presents clinically as purple, itchy papules and plaques on the lower back, body folds, oral mucosa, and on the scalp(1). it is recurrent condition with a prolonged course and requires an effective, safer and relatively cheaper treatment option (2). objective: "to compare the efficacy of oral methotrexate vs. oral acitretin in the treatment of generalized lichen planus". material \& methods: this randomized comarative study will be carried out in outpatient dermatology department, sheikh zayed hospital rahim yar khan, pakistan. approval of the study has been taken from ethical review committee of the hospital.data will be collected on prescribed form. patient will be selected on basis of inclusion \& exclusion criteria. informed consent will be taken from selected patients before data collection. study will include 124 patients which will be divided into 2 groups a \& b, 62 in each group. group a will receive oral methotrexate 10mg once weekly for 12 weeks. group b will receive oral acitretin 50mg daily for 12 weeks. folic acid will be given to all patients in group a at a dose of five milligram per day. patient will be followed at 4 weekly interval and final efficacy will be determined at 12th week.data will be analyzed by spss v25.0.

Eligibility criteria:
inclusion criteria: * age: 18-60 years * gender: both male and female * type of lichen planus: generalized lichen planus * patients not taking prior treatment in last 1 month exclusion criteria: * pregnancy and lactating females * bleeding disorders * abnormal liver function tests * platelet count less than 100000 * hypersensitivity to methotrexate or acitretin * unrealistic expectations

Keywords: lichen planus acitretin methotrexate efficacy